Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Low-dose tamoxifen (5mg/day) significantly reduces breast cancer recurrence with minimal toxicity over 10 years. Benign gynecological and breast events were similar to placebo, reinforcing its favorable safety profile.
Area Of Science
- Oncology
- Pharmacology
- Clinical Trials
Background
- Tamoxifen is effective for breast cancer prevention but limited by side effects.
- A previous phase III trial demonstrated low-dose tamoxifen (5 mg/day) efficacy in reducing recurrence with minimal toxicity.
Purpose Of The Study
- To evaluate the long-term (10-year) safety and incidence of benign gynecological and breast events associated with low-dose tamoxifen therapy for breast cancer prevention.
Main Methods
- A 10-year follow-up of a phase III trial comparing low-dose tamoxifen (5 mg/day) against a placebo.
- Systematic monitoring and reporting of benign gynecological events (uterine, ovarian) and breast events.
Main Results
- No significant differences in benign gynecological or breast events were observed between the low-dose tamoxifen and placebo groups after 10 years.
- The uterus was the most frequently affected site, with similar rates of endometrial polyps in both arms.
- Endometrial thickness remained stable in premenopausal women and showed a minimal, non-clinically significant increase in postmenopausal women on low-dose tamoxifen.
Conclusions
- Low-dose tamoxifen exhibits a favorable long-term safety profile for breast cancer prevention.
- The incidence of benign events with low-dose tamoxifen is lower compared to standard-dose tamoxifen.
- Low-dose tamoxifen represents a safe and effective option for breast cancer risk reduction.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...